TSC2 and lymphangioleiomyomatosis: TSC, TSC-LAM, and S-LAM patients typically possess inactivating mutations in TSC1 or, much more commonly, TSC2 (Smolarek et al., 1998; Carsillo et al., 2000; Sato et al., 2002).